摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-methyl-3-pentenyl)-4-piperidone | 203321-74-8

中文名称
——
中文别名
——
英文名称
1-(4-methyl-3-pentenyl)-4-piperidone
英文别名
1-(4-Methylpent-3-enyl)piperidin-4-one
1-(4-methyl-3-pentenyl)-4-piperidone化学式
CAS
203321-74-8
化学式
C11H19NO
mdl
——
分子量
181.278
InChiKey
TTWDGFOQVSMBDK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    13
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.73
  • 拓扑面积:
    20.3
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-(4-methyl-3-pentenyl)-4-piperidone乙酸铵 、 sodium cyanoborohydride 作用下, 以 甲醇 为溶剂, 生成 1-(4-methyl-3-pentenyl)-4-aminopiperidine
    参考文献:
    名称:
    Fluorine-containing 1,4-disubstituted piperidine derivatives
    摘要:
    含氟的新型1,4-二取代哌啶衍生物,通式\x9bI! ##STR1##例如,(2R)-N-\x9b1-(6-氨基吡啶-2-基甲基)哌啶-4-基!-2-\x9b(1R)-3,3-二氟环戊基!-2-羟基-2-苯乙酰胺或其药用盐,是对M.sub.3受体具有强效和选择性拮抗作用的化合物,副作用很小。通式\x9bI!的化合物表现出优异的口服活性、活性持续时间和药代动力学。它们可用于治疗和预防呼吸系统疾病,如慢性阻塞性肺疾病;泌尿系统疾病,如尿失禁;以及消化系统疾病,如肠易激综合征和晕动病。
    公开号:
    US05948792A1
  • 作为产物:
    描述:
    5-溴-2-甲基-2-戊烯4-氧代哌啶酮盐酸盐potassium carbonate 、 potassium iodide 作用下, 以 乙腈 为溶剂, 反应 7.0h, 以97%的产率得到1-(4-methyl-3-pentenyl)-4-piperidone
    参考文献:
    名称:
    J-104129, a novel muscarinic M3 receptor antagonist with high selectivity for M3 over M2 receptors
    摘要:
    A new class of 4-acetamidopiperidine derivatives has been synthesized and investigated for human muscarinic receptor subtype selectivity. Introduction of a hydrocarbon chain of appropriate length into the piperidine nitrogen of the racemic N-(piperidin-4-yl)-2-cyclobutyl-2-hydroxy-2-phenylacetamide platform conferred up to 70-fold selectivity for human muscarinic M-3 receptors over M-2 receptors. Subsequent synthetic derivatizations resulted in highly potent M-3 receptor antagonists with selectivity greater than two orders of magnitude for M-3 over M-2 receptors, from which the analogue 4r was selected. Preparation of both enantiomers of 4r led to the identification of (2R)-N-[1-(4-methyl-3-pentenyl)piperidin-4-yl]-2-cyclopentyl-2-hydroxy-2-phenylacetamide (J-104129, (R)-4r), which exhibited 120-fold selectivity for Mg receptors (K-i = 4.2 nM) over M-2 receptors (K-i = 490 nM). In isolated rat trachea, (R)-4r potently and specifically antagonized acetylcholine (ACh)-induced responses with a K-B value of 3.3 nM. The highly subtype-selective profile was also seen in isolated rat tissue assays (50-fold) and in anesthetized rats (> 250-fold). Oral administration of J-104129 ((R)-4r) antagonized ACh-induced bronchoconstriction with an ED50 value of 0.58 mg/kg in rats. Thus, J-104129 ((R)-4r) may effectively facilitate bronchodilation in the treatment of obstructive airway disease. (C) 1999 Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0968-0896(99)00177-7
点击查看最新优质反应信息

文献信息

  • Fluorine-containing 1,4-disubstituted piperidine derivatives
    申请人:Banyu Pharmaceutical Co., Ltd.
    公开号:US05948792A1
    公开(公告)日:1999-09-07
    Novel fluorine-containing 1,4-disubstituted piperidine derivatives, represented by general formula \x9bI! ##STR1## such as, for example, (2R)-N-\x9b1-(6-aminopyridin-2-ylmethyl)piperidin-4-yl!-2-\x9b(1R)-3,3-difluoroc yclopentyl!-2-hydroxy-2-phenylacetamide or pharmaceutically acceptable salt thereof, are potent and selective antagonists for muscarinic M.sub.3 receptors with little side effects. The compounds of formula \x9bI! exhibit excellent oral activity, duration of activity and pharmacolkinetics. They are useful for treatment and prophylaxis of respiratory diseases, such as chronic obstructive pulmonary diseases; urinary diseases, such as urinary incontinence; and digestive diseases, such as irritable bowel syndrome, and motion sickness.
    含氟的新型1,4-二取代哌啶衍生物,通式\x9bI! ##STR1##例如,(2R)-N-\x9b1-(6-氨基吡啶-2-基甲基)哌啶-4-基!-2-\x9b(1R)-3,3-二氟环戊基!-2-羟基-2-苯乙酰胺或其药用盐,是对M.sub.3受体具有强效和选择性拮抗作用的化合物,副作用很小。通式\x9bI!的化合物表现出优异的口服活性、活性持续时间和药代动力学。它们可用于治疗和预防呼吸系统疾病,如慢性阻塞性肺疾病;泌尿系统疾病,如尿失禁;以及消化系统疾病,如肠易激综合征和晕动病。
  • FLUORINATED 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES
    申请人:BANYU PHARMACEUTICAL CO., LTD.
    公开号:EP0930298B1
    公开(公告)日:2002-12-18
  • US5948792A
    申请人:——
    公开号:US5948792A
    公开(公告)日:1999-09-07
  • US6040449A
    申请人:——
    公开号:US6040449A
    公开(公告)日:2000-03-21
  • J-104129, a novel muscarinic M3 receptor antagonist with high selectivity for M3 over M2 receptors
    作者:Morihiro Mitsuya、Toshiaki Mase、Yoshimi Tsuchiya、Kumiko Kawakami、Hiromi Hattori、Kensuke Kobayashi、Yoshio Ogino、Toru Fujikawa、Akio Satoh、Toshifumi Kimura、Kazuhito Noguchi、Norikazu Ohtake、Koji Tomimoto
    DOI:10.1016/s0968-0896(99)00177-7
    日期:1999.11
    A new class of 4-acetamidopiperidine derivatives has been synthesized and investigated for human muscarinic receptor subtype selectivity. Introduction of a hydrocarbon chain of appropriate length into the piperidine nitrogen of the racemic N-(piperidin-4-yl)-2-cyclobutyl-2-hydroxy-2-phenylacetamide platform conferred up to 70-fold selectivity for human muscarinic M-3 receptors over M-2 receptors. Subsequent synthetic derivatizations resulted in highly potent M-3 receptor antagonists with selectivity greater than two orders of magnitude for M-3 over M-2 receptors, from which the analogue 4r was selected. Preparation of both enantiomers of 4r led to the identification of (2R)-N-[1-(4-methyl-3-pentenyl)piperidin-4-yl]-2-cyclopentyl-2-hydroxy-2-phenylacetamide (J-104129, (R)-4r), which exhibited 120-fold selectivity for Mg receptors (K-i = 4.2 nM) over M-2 receptors (K-i = 490 nM). In isolated rat trachea, (R)-4r potently and specifically antagonized acetylcholine (ACh)-induced responses with a K-B value of 3.3 nM. The highly subtype-selective profile was also seen in isolated rat tissue assays (50-fold) and in anesthetized rats (> 250-fold). Oral administration of J-104129 ((R)-4r) antagonized ACh-induced bronchoconstriction with an ED50 value of 0.58 mg/kg in rats. Thus, J-104129 ((R)-4r) may effectively facilitate bronchodilation in the treatment of obstructive airway disease. (C) 1999 Elsevier Science Ltd. All rights reserved.
查看更多